The Pioneer
The frontier and an appetite for the unknown, goes first.
Robert Bradway presents as a Pioneer leader whose conviction in frontier science drives long-cycle, high-stakes bets. In this interview, Bradway articulates a deliberate strategy of pursuing genetically validated, first-in-class therapies, anchored by Amgen's 2012 acquisition of Decode Genetics in Iceland.
“We are plowing new fields. When you're developing a first-in-class medicine, you can't rely on the data that others have generated through time to show that the outcome you're intending to achieve is likely to happen.”
On the risk of first-in-class drug developmentundated
“You finish the $2.5 billion of investment, and only then you turn over the card to see whether you've been successful in preventing cardiovascular events by lowering the parameter that you were trying to lower.”
On the economics of drug discoveryundated
“About two-thirds of our molecules are ones which we believe are genetically validated. We're pursuing them because we believe we have genetic evidence to suggest that if we perturb the pathway we're intercepting, we can have a beneficial outcome.”
On the genetics-driven pipelineundated
Money Maze Podcast: “Money Maze Vignettes: Iceland’s Vital Role in Pharmaceutical Research (With Robert Bradway, CEO of Amgen)”
LISTEN AT THE SOURCE ↗THE RECORD IS CHECKABLE